QMS Medical Allied Services Signs Five-Year Exclusive Distribution Agreement with HEINE Optotechnik
Mumbai, August 27, 2026: QMS Medical Allied Services Limited has entered into a five-year exclusive marketing and distribution agreement with HEINE Optotechnik, a global manufacturer of primary diagnostic instruments.
Under the agreement, QMS Medical Allied Services will become the sole distributor of HEINE’s range of primary diagnostic instruments in India. The partnership is expected to strengthen QMS’s product business and provide an additional growth opportunity in India’s expanding healthcare market.
QMS Medical Allied Services is listed on the NSE under the symbol QMSMEDI.
Five-Year Exclusive Agreement Begins January 2027
The agreement was signed on August 27, 2026, at HEINE Optotechnik’s headquarters in Gilching, Germany.
The exclusive arrangement will commence on January 1, 2027, and will remain valid for five years.
As part of the agreement, HEINE will not appoint or supply any other distributor, dealer or commercial partner for the specified products in India, either directly or indirectly.
This gives QMS an exclusive position for the distribution of HEINE’s covered product portfolio across the Indian market.
HEINE India Business Provides Growth Opportunity
According to QMS Medical Allied Services, HEINE’s net revenues from the Indian market are expected to be approximately €2.6 million, or around ₹30 crore, in calendar year 2026.
QMS expects the turnover generated through the partnership to increase to approximately ₹70 crore by 2031.
The expected growth represents a significant opportunity for QMS’s product business as it leverages its pan-India distribution capabilities and established presence in the healthcare ecosystem.
Wide Range of Diagnostic Products
The agreement covers a broad portfolio of HEINE products across several medical categories.
The covered products include:
- General medicine and ENT instruments
- Dermatoscopes and digital documentation solutions
- Ophthalmic instruments
- Laryngoscopes
- Loupes and headlights
- Veterinary diagnostic instruments
- Power sources
- Bulbs
- Cases
- Spare parts
- Specialised products
The broad product portfolio allows QMS to address multiple healthcare and diagnostic requirements across different customer segments.
QMS Aims to Accelerate Product Business Growth
The exclusive HEINE partnership is expected to support QMS Medical Allied Services’ strategy of expanding its product business.
The company already has an established presence across India’s healthcare market. By adding HEINE’s internationally recognised diagnostic instruments to its distribution portfolio, QMS aims to leverage its existing network and customer relationships.
The company expects the partnership to accelerate growth over the next five years while creating opportunities to expand its presence in India’s healthcare products market.
Management Commentary
Mahesh Makhija, Chairman & Managing Director of QMS Medical Allied Services, said the company was pleased to welcome HEINE Optotechnik to the QMS portfolio.
He described the exclusive partnership as an important part of the company’s product business expansion strategy and said it could help accelerate QMS’s growth trajectory over the next five years.
Management also highlighted the opportunity to leverage QMS’s wider presence and established reputation in India’s growing healthcare market.
About HEINE Optotechnik
HEINE Optotechnik began operations in 1946 and has developed into a leading manufacturer of primary diagnostic instruments.
The company develops and manufactures its instruments at facilities in Germany, combining its long-standing expertise with modern manufacturing technologies.
HEINE has a presence in more than 120 countries and operates through subsidiaries in markets including Australia, the United States, Canada and Switzerland. Its global network also includes approximately 3,000 representatives, importers and specialist dealers.
The company has around 500 employees and remains a family-owned enterprise.
QMS Medical Allied Services’ Growth Strategy
QMS Medical Allied Services operates as an integrated healthcare solutions company with activities spanning both healthcare products and healthcare services.
Its capabilities include:
- Patient engagement
- Patient Service Programs (PSPs)
- Disease management
- Preventive healthcare initiatives
- Patient screening and medical camps
- Healthcare staffing
- Medical and diagnostic solutions
The company works with pharmaceutical companies, healthcare providers and patients to improve access to healthcare, support continuity of care and contribute to healthcare outcomes.
QMS Targets ₹500 Crore Revenue by FY29
QMS Medical Allied Services said it has set an ambitious target of surpassing ₹500 crore in revenue by FY29.
The company’s growth strategy is based on two key engines: a scalable product business and a high-growth services portfolio.
The HEINE agreement strengthens the product side of this strategy by adding an exclusive international medical-device portfolio to QMS’s distribution business.
The company also noted that it migrated to the NSE mainboard in June 2026, marking another development in its evolution as a listed healthcare company.
Strong Healthcare Network
QMS Medical Allied Services describes itself as India’s only listed player with a demonstrated presence and market share across preventive healthcare management and pharma marketing segments.
The company currently serves more than 10 lakh patients and has partnered with over 50 leading pharmaceutical and healthcare companies across India.
Its established healthcare network could provide a platform for expanding the distribution of HEINE’s diagnostic products across the country.
Key Takeaways for Investors
The major highlights of the announcement are:
- QMS Medical Allied Services signed a five-year exclusive agreement with HEINE Optotechnik.
- QMS will become the sole distributor of covered HEINE products in India.
- The agreement starts on January 1, 2027.
- HEINE’s Indian net revenue is expected to be around €2.6 million (~₹30 crore) in 2026.
- QMS expects the partnership turnover to reach around ₹70 crore by 2031.
- The agreement covers diagnostic instruments across medicine, ENT, dermatology, ophthalmology and veterinary applications, among others.
- The partnership is expected to strengthen QMS’s product business.
- QMS aims to surpass ₹500 crore revenue by FY29.
- The company serves more than 10 lakh patients and works with 50+ pharmaceutical and healthcare companies.
What the HEINE Partnership Means for QMS
The exclusive distribution agreement with HEINE represents a significant business development for QMS Medical Allied Services, particularly for its product vertical.
The combination of HEINE’s established diagnostic instrument portfolio and QMS’s pan-India distribution capabilities could create an additional growth channel for the company. The exclusivity of the agreement also provides QMS with a differentiated position in distributing the covered HEINE products in India.
For investors, the key factors to track will be product sales growth, distribution expansion, revenue contribution from HEINE, execution of the five-year agreement, margins and progress towards QMS’s ₹500 crore FY29 revenue target.
Overall, the partnership provides QMS Medical Allied Services with a new opportunity to expand its healthcare products business while strengthening its presence in India’s growing medical and diagnostic market.
Disclaimer: This article is based on information disclosed by QMS Medical Allied Services Limited in its regulatory filing and press release dated August 27, 2026. The revenue projections and other forward-looking statements are based on management expectations and are subject to business, market and other risks. This article is for informational purposes only and should not be considered investment advice.